A recent pilot clinical trial (NCT 03728335) assessed the use of Enasidenib as a post-HSCT maintenance therapy for 15 patients with IDH2-mutated AML: the patients received 24 cycles of Enasidenib therapy with leukemia-free survival rates of 100%, chromic GVHD-free survival rates of 93%, and relapse-free survival rates of 87% [58]. Here, IDH2 is linked to acute myeloid leukemia.